EcoDrugPlus

Alpha-Amylase 2b

Ensembl ID : ENSBTAG00000024288
Gene Symbol: LOC539383
3 Enzyme and pathways 4 Cross references
212 Possible Orthologues:

Amine Oxidase Copper Containing 1

Ensembl ID : ENSBTAG00000005419
Gene Symbol: AOC1
6 Enzyme and pathways 5 Cross references
246 Possible Orthologues:

Amine Oxidase Copper Containing 3

Ensembl ID : ENSBTAG00000030333
Gene Symbol: AOC3
3 Enzyme and pathways 4 Cross references
320 Possible Orthologues:

Amine Oxidase, Copper Containing 3

Ensembl ID : ENSBTAG00000039321
Gene Symbol: SAO
3 Enzyme and pathways 4 Cross references
321 Possible Orthologues:

Amylase, Alpha 2b (Pancreatic)

Ensembl ID : ENSBTAG00000019093
Gene Symbol: AMY2B
3 Enzyme and pathways 4 Cross references
211 Possible Orthologues:

Amyloid P Component, Serum

Ensembl ID : ENSBTAG00000019616
Gene Symbol: APCS
5 Cross references
414 Possible Orthologues:

Amyloid Beta Precursor Protein

Ensembl ID : ENSBTAG00000017753
Gene Symbol: APP
46 Enzyme and pathways 5 Cross references
292 Possible Orthologues:

Androgen Receptor

Ensembl ID : ENSBTAG00000022255
Gene Symbol: AR
23 Enzyme and pathways 5 Cross references
291 Possible Orthologues:

Angiotensin I Converting Enzyme

Ensembl ID : ENSBTAG00000024950
Gene Symbol: ACE
3 Enzyme and pathways 5 Cross references
104 Possible Orthologues:

Angiotensin Ii Receptor Type 1

Ensembl ID : ENSBTAG00000045633
Gene Symbol: AGTR1
11 Enzyme and pathways 5 Cross references
226 Possible Orthologues:

Angiotensin Ii Receptor Type 2

Ensembl ID : ENSBTAG00000040386
Gene Symbol: AGTR2
7 Enzyme and pathways 5 Cross references
207 Possible Orthologues:

Apelin Receptor

Ensembl ID : ENSBTAG00000027516
Gene Symbol: APLNR
7 Enzyme and pathways 5 Cross references
184 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).